StudyManager today announced that Meagan Medical, Inc., a clinical research and product development company, has deployed StudyManager Evolve software to manage its latest clinical study.
“We are seeing more and more Evolve interest in the medical device market and are pleased that our Evolve software will help play a key role in Meagan Medical’s study,” said Jeff West, Director, Professional Services, StudyManager. “ It’s been exciting to work with the Meagan Medical team from startup, helping ensure the study stayed on track.”
Evolve's Web-based interface integrates clinical trial management and electronic data capture tools. These features are extremely scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.